Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 with Chemo-radiotherapy in LS-SCLC
NCT04691063Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jan 2021
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Hengrui. Status: unknown.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04691063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691063.